ASCP Launches $250K Grants for mCRC Biomarker Testing with Pfizer, ASCO
The American Society for Clinical Pathology (ASCP), in collaboration with Pfizer (NYSE: PFE) and with participation...
Boehringer Ingelheim Licenses Simcere’s SIM0709 Bispecific for Inflammatory Bowel Disease
Boehringer Ingelheim and Simcere Pharmaceutical Group (HKG: 2096) announced a licensing and collaboration agreement to...
Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency
Visen Pharmaceuticals (HKG: 2561), a joint venture between Ascendis Pharma (Denmark) and Vivo Capital, announced...
Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture
Sunshine Lake Pharma Co., Ltd. (HKG: 6887) and Xtalpi Inc. (HKG: 2228) announced plans to...
HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing
HanchorBio, Inc. and WuXi Biologics (HKG: 2269) announced a strategic collaboration under which WuXi Biologics will...
Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in a 13‑week...
Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
Knature Biopharmaceutical Co., Ltd. announced it has filed for an initial public offering (IPO) with...
Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge
Sanofi (NASDAQ: SNY) announced positive results from two global Phase III studies (SHORE and COAST 2) for amlitelimab,...
MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that its Talos straight thoracic aortic...
Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy
Huahui Health announced that China’s National Medical Products Administration (NMPA) has granted conditional approval for...
GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing
GenEditBio announced a joint development agreement with uBriGene Biosciences International Co. to advance next‑generation lipid...
AstraZeneca’s Soliris Wins NMPA Approval for Pediatric Myasthenia Gravis
AstraZeneca plc (AZ, NASDAQ: AZN) announced that China’s National Medical Products Administration (NMPA) has approved Soliris...
Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute
Merck & Co. Inc. (MSD, NYSE: MRK) has reportedly ended acquisition talks with Revolution Medicines after the...
Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets
Dizal Pharmaceutical Co., Ltd. (SHA: 688192), the China‑based joint venture established by AstraZeneca (AZ, NASDAQ: AZN)...
Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that China’s National Medical Products Administration (NMPA)...
Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that China’s National Medical Products...
Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing
Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug...
HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance
Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company...
Daiichi Sankyo Secures Breakthrough Therapy Designation for CDH6‑Targeted ADC Raludotatug Deruxtecan in Ovarian Cancer
Daiichi Sankyo (TYO: 4568) announced that Raludotatug Deruxtecan (R‑DXd, DS‑6000a), a first‑in‑class CDH6‑targeted antibody‑drug conjugate (ADC),...
Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy
Novo Nordisk (NYSE: NVO) and Canadian biotechnology firm Aspect Biosystems announced a new phase in their...